EGFR and non-small cell lung carcinoma: It has been demonstrated that MET inhibitors in combination with EGFR-TKIs can overcome EGFR-TKI resistance mediated by aberrant c-Met activation in NSCLC preclinical models [35, 36]; however, the efficacy and survival data of such patients treated with crizotinib have rarely been published.